EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity

Henry Sutanto iD, Mukti Citra Ningtyas, Betty Rachma iD, Laras Pratiwi, Deasy Fetarayani iD

Immunology & Cell Biology · 2025-08 · 103 (7) · 696-722

DOI: 10.1111/imcb.70043 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology & Cell Biology, online erschienen am 26.06.2025. Verfasst von Henry Sutanto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. Hauptthemen laut MEDLINE: Neoplasms, Th17 Cells, Cell Plasticity. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 185 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐helper 17 (Th17) cells, a subset of CD4 + T cells, are key players in mucosal immunity and inflammation, distinguished by their production of IL‐17 and related cytokines. In the context of cancer, Th17 cells exhibit extraordinary plasticity—adapting their phenotype and function in response to tumor microenvironmental cues. This review explores how Th17 cells mediate paradoxical roles in tumor biology, promoting either tumor progression or antitumor immunity depending on molecular context. Protumorigenic functions include fostering angiogenesis, chronic inflammation and immune evasion through IL‐17‐driven recruitment of neutrophils and myeloid‐derived suppressor cells. Conversely, Th17 cells can transition into IFNγ‐producing Th1‐like cells, enhancing cytotoxic T‐cell responses and tumor rejection. Key modulators of this plasticity include cytokines (IL‐23, IL‐12, TGF‐β), hypoxia, metabolic shifts and epigenetic reprogramming. We further examine how Th17 plasticity contributes to metastasis, therapy resistance and immune modulation via interactions with tumor‐associated macrophages and regulatory T cells. Finally, the review highlights emerging therapeutic strategies that target Th17 pathways through cytokine blockade, metabolic intervention, RORγ modulation and adoptive cell therapy. Understanding Th17 plasticity provides critical insights into tumor immunology and offers novel avenues for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTh17 CellsCell PlasticityHumansAnimalsTumor MicroenvironmentCytokines

Stichwörter der Autor:innen

ImmunologyTh17T‐helper lymphocyteoncologyplasticity

Substanzen

Cytokines

Autor:innen und Institutionen

  • Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
  • Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

ORCID-Profile: Henry Sutanto, Betty Rachma, Deasy Fetarayani

Zitieren

APA

Sutanto, H., Ningtyas, M. C., Rachma, B., Pratiwi, L., & Fetarayani, D. (2025). Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity. Immunology & Cell Biology, 103(7), 696-722. https://doi.org/10.1111/imcb.70043

Vancouver

Sutanto H, Ningtyas MC, Rachma B, Pratiwi L, Fetarayani D. Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity. Immunology & Cell Biology. 2025;103(7):696-722. doi:10.1111/imcb.70043

BibTeX
@article{Sutanto2025,
  author = {Sutanto, Henry and Ningtyas, Mukti Citra and Rachma, Betty and Pratiwi, Laras and Fetarayani, Deasy},
  title = {Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity},
  journal = {Immunology & Cell Biology},
  year = {2025},
  volume = {103},
  number = {7},
  pages = {696--722},
  doi = {10.1111/imcb.70043}
}
Kostenlos starten →